Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Lymphoid 4Other hematologic neoplasm 3Sarcoma 2Gynecologic 2Genitourinary 2Plasma cell 1Dermatologic 1Classical hematology 1CNS 1Breast 1

Conditions

Neuroblastoma 60Central Nervous System Neoplasms 39Brain Neoplasms 34Medulloblastoma 26Astrocytoma 15Rhabdoid Tumor 12Glioblastoma 12Ependymoma 12Sarcoma 10Glioma 9Testicular Neoplasms 8Oligodendroglioma 7Choroid Plexus Neoplasms 7Teratoma 6Optic Nerve Glioma 6Neuroectodermal Tumors, Primitive, Peripheral 6Gliosarcoma 6Testicular Germ Cell Tumor 5Retinoblastoma 5Neuroectodermal Tumors, Primitive 5Neoplasms 5Lymphoma 5Recurrence 4Ovarian Neoplasms 4Ganglioneuroblastoma 4Familial ependymoma 4Carcinoma, Renal Cell 4Spinal Cord Neoplasms 3Rhabdomyosarcoma 3Osteosarcoma 3

Interventions

sodium thiosulfate 3Filgrastim 3Carboplatin 3etoposide phosphate 2Cyclophosphamide 2pegfilgrastim 1Vincristine 1Trastuzumab 1Temozolomide 1Rituximab 1Procarbazine 1Methotrexate 1Mannitol 1Lomustine 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Genetic Therapy 1Etoposide 1Cytarabine 1Cefixime 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Etoposide × CNS × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡